Enzymatic degradation of heparin-modified hydrogels and its effect on bioactivity

Biomaterials

Volumn 33, Issue 22, 2012, Pages 5534-5540

  Nilasaroya, Anastasia ^a   Martens, Penny J ^a   Whitelock, John M ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Degradation; Enzyme; Growth factors; Heparanase; Heparin; Hydrogel

Indexed keywords

ANTI-COAGULATION; ANTICOAGULATION PROPERTIES; BLOOD CLOT FORMATION; BLOOD PRODUCTS; CELL RECEPTORS; DUAL EFFECT; ENZYMATIC DEGRADATION; EXTRACELLULAR MATRICES; GROWTH FACTOR; HEPARAN SULFATES; HEPARANASE; HEPARIN; TISSUE REPAIR; TISSUE-ENGINEERED SCAFFOLDS;

BIOACTIVITY; CELL MEMBRANES; DEGRADATION; ENZYMES; PLATELETS; POLYSACCHARIDES; TISSUE;

HYDROGELS;

FIBROBLAST GROWTH FACTOR 2; HEPARAN SULFATE; HEPARANASE; HEPARIN; POLYVINYL ALCOHOL; TISSUE SCAFFOLD;

ANIMAL CELL; ANTICOAGULATION; ARTICLE; BLOOD CLOTTING; CONTROLLED STUDY; ENZYMATIC DEGRADATION; HUMAN; HYDROGEL; INJURY; MOLECULAR WEIGHT; NONHUMAN; PRIORITY JOURNAL; THROMBOCYTE; TISSUE REPAIR;

CELL LINE; CELL SURVIVAL; GLUCURONIDASE; HEPARIN; HUMANS; HYDROGELS; MATERIALS TESTING;

EID: 84861225159     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2012.04.022     Document Type: Article

References (39)

1. Whitelock J.M., Iozzo R.V. Heparan sulfate: a complex polymer charged with biological activity. Chem Rev 2005, 105:2745-2764.
2. Levy-Adam F., Abboud-Jarrous G., Guerrini M., Beccati D., Vlodavsky I., Ilan N. Identification and characterization of heparin/heparan sulfate binding domains of the endoglycosidase heparanase. J Biol Chem 2005, 280:20457-20466.
3. Sanderson R.D., Yang Y., Suva L.J., Kelly T. Heparan sulfate proteoglycans and heparanase - partners in osteolytic tumor growth and metastasis. Matrix Biol 2004, 23:341-352.
4. Reiland J., Sanderson R.D., Waguespack M., Barker S.A., Long R., Carson D.D., et al. Heparanase degrades syndecan-1 and perlecan heparan sulfate: functional implications for tumor cell invasion. J Biol Chem 2004, 279:8047-8055.
5. Nakajima M., Irimura T., Di Ferrante N., Nicolson G.L. Metastatic melanoma cell heparanase. Characterization of heparan sulfate degradation fragments produced by B16 melanoma endoglucuronidase. J Biol Chem 1984, 259:2283-2290.
6. Bame K.J. Heparanases: endoglycosidases that degrade heparan sulfate proteoglycans. Glycobiology 2001, 11:91R-98R.
7. Hulett M.D., Freeman C., Hamdorf B.J., Baker R.T., Harris M.J., Parish C.R. Cloning of mammalian heparanase, an important enzyme in tumor invasion and metastasis. Nat Med 1999, 5:803-809.
8. Vlodavsky I., Friedmann Y., Elkin M., Aingorn H., Atzmon R., Ishai-Michaeli R., et al. Mammalian heparanase: Gene cloning, expression and function in tumor progression and metastasis. Nat Med 1999, 5:793-802.
9. Whitelock J.M., Melrose J., Iozzo R.V. Diverse cell signaling events modulated by perlecan. Biochemistry 2008, 47:11174-11183.
10. Vlodavsky I., Miao H.-Q., Medalion B., Danagher P., Ron D. Involvement of heparan sulfate and related molecules in sequestration and growth promoting activity of fibroblast growth factor. Cancer Metastasis Rev 1996, 15:177-186.
11. Freeman C., Parish C.R. A rapid quantitative assay for the detection of mammalian heparanase activity. Biochem J 1997, 325:229-237.
12. Gilat D., Hershkoviz R., Goldkorn I., Cahalon L., Korner G., Vlodavsky I., et al. Molecular behavior adapts to context: heparanase functions as an extracellular matrix-degrading enzyme or as a T cell adhesion molecule, depending on the local pH. J Exp Med 1995, 181:1929-1934.
13. Graham L., Hayward I., Underwood P. Activation of platelet heparitinase by vascular cell lysates. Biochem Mol Biol Int 1995, 37:231-237.
14. Drury J.L., Mooney D.J. Hydrogels for tissue engineering: scaffold design variables and applications. Biomaterials 2003, 24:4337-4351.
15. Bryant S.J., Davis-Arehart K.A., Luo N., Shoemaker R.K., Arthur J.A., Anseth K.S. Synthesis and characterization of photopolymerized multifunctional hydrogels: Water-soluble poly(vinyl alcohol) and chondroitin sulfate macromers for chondrocyte encapsulation. Macromolecules 2004, 37:6726-6733.
16. Ehrbar M., Rizzi S.C., Schoenmakers R.G., San Miguel B., Hubbell J.A., Weber F.E., et al. Biomolecular hydrogels formed and degraded via site-specific enzymatic reactions. Biomacromolecules 2007, 8:3000-3007.
17. Takagaki K., Kakizaki I. Degradation of glycosaminoglycans. Comprehensive glycoscience 2007, 171-192. Oxford: Elsevier. J.P. Kamerling (Ed.).
18. Whitelock J.M., Murdoch A.D., Iozzo R.V., Underwood P.A. The degradation of human endothelial cell-derived perlecan and release of bound basic fibroblast growth factor by stromelysin, collagenase, plasmin, and heparanases. J Biol Chem 1996, 271:10079-10086.
19. Kjellen L., Lindahl U. Proteoglycans: Structures and interactions. Annu Rev Biochem 1991, 60:443-475.
20. Nilasaroya A., Poole-Warren L.A., Whitelock J.M., Martens P.J. Structural and functional characterisation of poly(vinyl alcohol) and heparin hydrogels. Biomaterials 2008, 29:4658-4664.
21. Lapierre F., Holme K., Lam L., Tressler R.J., Storm N., Wee J., et al. Chemical modifications of heparin that diminish its anticoagulant but preserve its heparanase-inhibitory, angiostatic, anti-tumor and anti-metastatic properties. Glycobiology 1996, 6:355-366.
22. Behzad F., Brenchley P.E.C. A multiwell format assay for heparanase. Anal Biochem 2003, 320:207-213.
23. Farndale R.W., Buttle D.J., Barrett A.J. Improved quantitation and discrimination of sulphated glycosaminoglycans by use of dimethylmethylene blue. Biochim Biophys Acta 1986, 883:173-177.
24. Padera R., Venkataraman G., Berry D., Godavarti R., Sasisekharan R. FGF-2/fibroblast growth factor receptor/heparin-like glycosaminoglycan interactions: a compensation model for FGF-2 signaling. FASEB J 1999, 13:1677-1687.
25. Freeman C., Parish C.R. Human platelet heparanase: purification, characterization and catalytic activity. Biochem J 1998, 330:1341-1350.
26. Barbosa I., Garcia S., Barbier-Chassefiere V., Caruelle J.-P., Martelly I., Papy-Garcia D. Improved and simple micro assay for sulfated glycosaminoglycans quantification in biological extracts and its use in skin and muscle tissue studies. Glycobiology 2003, 13:647-653.
27. Rosenberg R.D., Jordan R.E., Favreau L.V., Lam L.H. Highly active heparin species with multiple binding sites for antithrombin. Biochem Biophys Res Commun 1979, 86:1319-1324.
28. Pikas D.S., Li J.-P., Vlodavsky I., Lindahl U. Substrate specificity of heparanases from human hepatoma and platelets. J Biol Chem 1998, 273:18770-18777.
29. Nasser N.J., Sarig G., Brenner B., Nevo E., Goldshmidt O., Zcharia E., et al. Heparanase neutralizes the anticoagulation properties of heparin and low-molecular-weight heparin. J Thromb Haemost 2006, 4:560-565.
30. Petitou M., Casu B., Lindahl U. 1976-1983, a critical period in the history of heparin: the discovery of the antithrombin binding site. Biochimie 2003, 85:83-89.
31. Turnbull J.E., Fernig D.G., Ke Y., Wilkinson M.C., Gallagher J.T. Identification of the basic fibroblast growth factor binding sequence in fibroblast heparan sulfate. J Biol Chem 1992, 267:10337-10341.
32. Pye D.A., Gallagher J.T. Monomer complexes of basic fibroblast growth factor and heparan sulfate oligosaccharides are the minimal functional unit for cell activation. J Biol Chem 1999, 274:13456-13461.
33. Guimond S., Maccarana M., Olwin B.B., Lindahl U., Rapraeger A.C. Activating and inhibitory heparin sequences for FGF-2 (basic FGF). Distinct requirements for FGF-1, FGF-2, and FGF-4. J Biol Chem 1993, 268:23906-23914.
34. Segev A., Nili N., Strauss B.H. The role of perlecan in arterial injury and angiogenesis. Cardiovasc Res 2004, 63:603-610.
35. Goodger S.J., Robinson C.J., Murphy K.J., Gasiunas N., Harmer N.J., Blundell T.L., et al. Evidence that heparin saccharides promote FGF2 mitogenesis through two distinct mechanisms. J Biol Chem 2008, 283:13001-13008.
36. Tans G., Rosing J., Thomassen M., Heeb M., Zwaal R., Griffin J. Comparison of anticoagulant and procoagulant activities of stimulated platelets and platelet-derived microparticles. Blood 1991, 77:2641-2648.
37. Oldberg A., Heldin C.H., Wasteson A., Busch C., Hook M. Characterization of platelet endoglycosidase degrading heparin-like polysaccharides. Biochemistry 1980, 19:5755-5762.
38. Iozzo R.V., Cohen I.R., Grässel S., Murdoch A.D. The biology of perlecan: the multifaceted heparan sulphate proteoglycan of basement membranes and pericellular matrices. Biochem J 1994, 302:625-639.
39. Hirsh J., Anand S.S., Halperin J.L., Fuster V. Guide to anticoagulant therapy: heparin: a statement for healthcare professionals from the American Heart Association. Circulation 2001, 103:2994-3018.